Sign inJoin waitlistJoin the waitlist

William Pao

Chief Executive Officer and Founder · Reveal Therapeutics, Inc

Credentials: · · · ·

History

Vanderbilt Univ Sch of Med
Present

Memorial Sloan Kettering Cancer Center
2000–2002
Internal Medicine
New York Presbyterian Hospital
1999–2000
NYP/Weill Cornell
1999–2000
Yale University
Yale MD-PhD Program

Research

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
Proceedings of the National Academy of Sciences of the United States of America · 2004 · First of 15 authors · Corresponding · 3,586 citations
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
Case report · PLoS Medicine · 2005 · First of 8 authors · Corresponding · 2,891 citations
Somatic mutations affect key pathways in lung adenocarcinoma
Nature · 2008 · 2,141 citations

ML
Marc Ladanyi
51 papers
MK
Mark Kris
50 papers
VM
Vincent Miller
50 papers
GR
Gregory Riely
38 papers · 17 as a fellow
MZ
Maureen Zakowski
25 papers
Christopher Azzoli
18 papers
Valerie Rusch
17 papers
Christine Lovly
16 papers · 7 as a fellow
MA
Maria Arcila
13 papers · 7 as a fellow
NR
Naiyer Rizvi
13 papers
Anthony Iafrate
11 papers
LH
Leora Horn
11 papers · 1 as a fellow

Grants

Targets for Therapy for Carcinomas of the Lung
National Cancer Institute · P01
Project lead · $2.9M · Sloan-Kettering Inst Can Research
2007–2018
Overcoming Acquired Resistance to EGFR Inhibitors in Lung Cancer
National Cancer Institute · R01
Contact PI · $2M · Vanderbilt University Medical Center
2007–2017
Elucidating Mechanisms of Lung Tumor Regression
National Cancer Institute · K08
Contact PI · $475.6K · Sloan-Kettering Inst Can Research
2005–2010

Clinical trials

Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes
Principal investigator · Terminated
Vanderbilt-Ingram Cancer Center
2009–2012
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
Vanderbilt-Ingram Cancer Center
2002–2013